Helgadottir H, et al. – This research ascertained how a family history of melanoma and germline CDKN2A mutation status of multiple primary melanomas (MPM) patients exerted an effect on the risks of developing subsequent melanomas and other cancers and survival outcomes. The findings illustrated that CDKN2A mutation status and family history of melanoma prominently affected the outcomes of MPM patients.